Last reviewed · How we verify
Adalimumab, Etanercept, Golimumab or infliximab
Adalimumab, Etanercept, Golimumab or infliximab is a Small molecule drug developed by University Hospital, Montpellier. It is currently in Phase 1 development.
At a glance
| Generic name | Adalimumab, Etanercept, Golimumab or infliximab |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
- Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (PHASE4)
- Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis (PHASE4)
- CHronic Nonbacterial Osteomyelitis International Registry
- Korean College of Rheumatology Biologics and Targeted Therapy Registry
- Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (PHASE4)
- Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab, Etanercept, Golimumab or infliximab CI brief — competitive landscape report
- Adalimumab, Etanercept, Golimumab or infliximab updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI
Frequently asked questions about Adalimumab, Etanercept, Golimumab or infliximab
What is Adalimumab, Etanercept, Golimumab or infliximab?
Adalimumab, Etanercept, Golimumab or infliximab is a Small molecule drug developed by University Hospital, Montpellier.
Who makes Adalimumab, Etanercept, Golimumab or infliximab?
Adalimumab, Etanercept, Golimumab or infliximab is developed by University Hospital, Montpellier (see full University Hospital, Montpellier pipeline at /company/university-hospital-montpellier).
What development phase is Adalimumab, Etanercept, Golimumab or infliximab in?
Adalimumab, Etanercept, Golimumab or infliximab is in Phase 1.